We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche is acquiring Good Therapeutics for $250 million in upfront cash, gaining Good’s conditionally active biologics (CAB) to create new immunotherapies for treating cancer. Read More
Novo Nordisk is beefing up its hematologic portfolio with the $1.1 billion acquisition of Forma Therapeutics, snagging the company’s late-stage sickle cell anemia candidate etavopivat. Read More
RSS
